Table 2.

Marker values on prostate cancer patients stratified by ±bone metastases and visit from the treatment study

BMVisit
01234
ααCTX (μg/mmol; ±SD)0.25 (0.17-0.19)0.23 (0.18-0.22)ns0.21 (0.18-0.23)ns0.23 (0.17-0.20)ns0.24 (0.18-0.21)ns
+0.89 (0.64-0.79)0.43 (0.25-0.29)**0.35 (0.23-0.27)*0.31 (0.20-0.25)*0.33 (0.19-0.22)**
tALP (units/L; ±SD)89 (54-62)76 (39-45)ns70 (35-40)ns76 (60-73)ns73 (38-43)ns
+246 (178-221)185 (142-178)ns125 (92-115)***111 (78-95)**120 (65-76)**
PSA (μg/L; ±SD)96 (170-263)120 (189-263)*115 (201-329)*56 (133-285)**44 (94-177)**
+115 (142-212)119 (141-205)**74 (109-179)**34 (57-103)**45 (67-111)***
  • Asterisks: Significant difference between PCa + BM or PCa − BM compared to baseline.